CVI Holdings’s Grace Therapeutics GRCE Stock Holding History

CVI Holdings’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,281	Closed	-$63K	–	76
2019 Q1	$63K	Buy	+1,281	New	+$63.2K	0.06%	39

Other funds holding GRCE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

CVI Holdings's GRCE Position: Q2 2019 in Review

CVI Holdings sold out of Grace Therapeutics (GRCE) in Q2 2019, closing a stake of 1,281 shares — an estimated $63K sold.

CVI Holdings first reported a position in GRCE in Q1 2019 and held it in 1 quarter. The position peaked at $63K in Q1 2019. 13 funds tracked by Wall St. Rank hold GRCE as of Q2 2019.

CVI Holdings reported no remaining Grace Therapeutics position as of Q2 2019 after selling out during the quarter.
CVI Holdings sold 1,281 Grace Therapeutics shares in Q2 2019, an estimated $63K.
CVI Holdings first reported a position in Grace Therapeutics in Q1 2019 and held it in 1 quarter.
CVI Holdings's Grace Therapeutics position peaked at $63K in Q1 2019.
13 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2019.

Based on CVI Holdings's 13F filing for Q2 2019, filed 14 Aug 2019.